Calcium Oxalate Stone Diseases (R01)

The summary for the Calcium Oxalate Stone Diseases (R01) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Calcium Oxalate Stone Diseases (R01)
	CFDA Number:	93.847
	CFDA Description:	Diabetes, Endocrinology and Metabolism Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Food and Nutrition Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	PA-09-213
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Jul 06, 2009
	Creation Date:	Jul 06, 2009
	Original Closing Date for Applications:	Sep 07, 2012
	Current Closing Date for Applications:	Sep 07, 2012
	Archive Date:	Oct 08, 2012
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	Information not provided
	Federal Grant Award Ceiling:	Information not provided
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Grant Description: Purpose. The purpose of this Funding Opportunity Announcement (FOA) is to increase investigator interest in research into oxalate metabolism, transport and homeostasis, and oxalate stone diseases. This initiative encourages basic, clinical or epidemiological studies that utilize new and innovative approaches to study the diagnosis, treatment and prevention of these disorders. Mechanism of Support. This FOA will utilize the NIH Research Project Grant (R01) grant mechanism. Funds Available and Anticipated Number of Awards. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/pa-09-213.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Pediatric Centers of Excellence in Nephrology (P50); • Nutrition Obesity Research Centers (P30); • George M. OBrien Kidney Research Core Centers (P30); • Cooperative Study Group for Autoimmune Disease Prevention (U01); • Collaborative Interdisciplinary Team Science in NIDDK Research Areas (R24); • PROTEOMIC AND METABOLOMIC APPROACHES TO DIAGNOSE DIABETES AND PRE-DIABETES; • MOLECULAR THERAPY CORE CENTERS; • PILOT AND FEASIBILITY PROGRAM IN HUMAN ISLET BIOLOGY; • DIABETES ENDOCRINOLOGY RESEARCH CENTERS; • CYSTIC FIBROSIS RESEARCH AND TRANSLATION CORE CENTERS